When Evidence Gap Becomes a Commercial Liability
The MENA evidence gap for selected portfolios is becoming a commercial liability for drugmakers that could have been prevented at the design stage.
Trump suggests, without evidence, that drugmakers are behind impeachment inquiry
Trump made the baseless remarks while speaking at an event in Florida to sign an executive order related to Medicare. His administration laid out plans to lower drug costs in a 2018 "blueprint."
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.